ATP1A3
ENSG00000105409
Target class
Transporter
Chromosome
19
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- ClinGen gene-disease validity
- Definitive
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- ATP1A3
- Gene name
- ATPase Na+/K+ transporting subunit alpha 3
- Gene symbol
- ATP1A3
- Previous gene symbols
- DYT12
- Protein name
- Sodium/potassium-transporting ATPase subunit alpha-3 (Na(+)/K(+) ATPase alpha-3 subunit) (EC 7.2.2.13) (Na(+)/K(+) ATPase alpha(III) subunit) (Sodium pump subunit alpha-3)
- Gene biotype
- Protein coding
- Gene family
- ATPase Na+/K+ transporting subunits
- Target class
- Transporter
- Target type
- Human gene
- Tissues expressed in
- 24
- Highest tissue expression
- 367.67
- Tissue specificity (Gini)
- 0.801
- Tissue specificity (tau)
- 0.885
- KEGG gene identifiers
- hsa:478
- Protein interaction confidence
- 0.842871
- Protein interaction partners
- 31
- R-HSA-5578775
- R-HSA-936837
- R-HSA-9679191
- End position
- 41997497
- Start position
- 41966582
- Chromosome
- 19
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
Publication evidence
- PubMed 7711835
- Tissue specificity (tau)
- 0.884674
- Expression inequality (Gini)
- 0.800986
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)
- 367.67
- Brain - Cerebellar Hemisphere
- 349.68
- Brain - Cerebellum
- 346.28
- Brain - Cortex
- 249.53
- Brain - Hypothalamus
- 209.17
Expression in transcripts per million
- Brain - Frontal Cortex (BA9)367.67
- Brain - Cerebellar Hemisphere349.68
- Brain - Cerebellum346.28
- Brain - Cortex249.53
- Brain - Hypothalamus209.17
- Brain - Anterior cingulate cortex (BA24)192.99
- Brain - Nucleus accumbens (basal ganglia)127.6
- Brain - Hippocampus124.76
- Brain - Amygdala91.84
- Heart - Left Ventricle91.6
- Brain - Caudate (basal ganglia)89.56
- Testis86.06
- Heart - Atrial Appendage78.36
- Brain - Putamen (basal ganglia)66.57
- Brain - Substantia nigra62.51
- Pituitary36.31
- Brain - Spinal cord (cervical c-1)21.62
- Colon - Sigmoid4.81
- Esophagus - Muscularis2.79
- Esophagus - Gastroesophageal Junction1.99
- Colon - Transverse1.93
- Small Intestine - Terminal Ileum1.91
- Spleen1.59
- Whole Blood1.06
- Cells - EBV-transformed lymphocytes0.74
And 29 more, listed on the interactive page.
- GO:0006883
- GO:0030007
- GO:0036376
- GO:0060075
- GO:0086064
- GO:1990535
- GO:1990573
- GO:0005783
- GO:0005794
- GO:0005886
- GO:0005890
- GO:0030424
- GO:0031090
- GO:0032809
- GO:0043025
- GO:1903561
- GO:0001540
- GO:0005391
- GO:0005515
- GO:0051087
atrioventricular block
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: atrioventricular block
- renal
- cardiovascular
PubMed 28216264decreased heart rate
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased heart rate
- renal
- cardiovascular
PubMed 28216264increased urine excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urine excretion
- renal
- cardiovascular
PubMed 28216264vomiting
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: vomiting
- renal
- cardiovascular
PubMed 28216264increased cardiac contractility
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased cardiac contractility
- renal
- cardiovascular
PubMed 28216264cardiac arrhythmia
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: cardiac arrhythmia
- renal
- cardiovascular
PubMed 28216264increased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- cardiovascular
PubMed 28216264ventricular fibrillation
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: ventricular fibrillation
- renal
- cardiovascular
PubMed 28216264
Related records
Trials (335)
- 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain
- A 3-Part, Open-Label, Drug-Drug Interaction Study of Concomitant Administration of E2609 With Itraconazole, Rifampin, Digoxin, or Donepezil
- A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
- A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
- A Clinical Study to Assess the Effect of Enlicitide on How the Body Processes Digoxin in Healthy Adult Participants (MK-0616-031)
- A Clinical Trial of Patients With Melanoma
- A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects
- A Clinical Trial to Investigate the Clinical Drug-Drug Interaction of Divarasib With Probe Substrates of P-Glycoprotein and Breast Cancer Resistance Protein in Healthy Participants
- A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
- A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants
- A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
- A Drug Drug Interaction Study to Evaluate the Effect of VCT220 on the Pharmacokinetics of Repaglinide, Rosuvastatin, and Digoxin in Healthy, Overweight, and Obese Subjects
- A Drug Interaction Study of ACH-0145228
- A Drug Interaction Study of Albiglutide and Digoxin
- A Drug-Drug Interaction (DDI) Study of HDM1002 With Repaglinide, Atorvastatin, Digoxin and Rosuvastatin in Healthy Subjects and Overweight Subjects.
- A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
- A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin
- A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants
- A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
- A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib
Drugs (6)
- Acetyldigitoxin Sodium/potassium-transporting ATPase inhibitor
- Deslanoside Sodium/potassium-transporting ATPase inhibitor
- Digitoxin Sodium/potassium-transporting ATPase inhibitor
- Digoxin Sodium/potassium-transporting ATPase inhibitor
- Istaroxime Sodium/potassium-transporting ATPase inhibitor
- Lanatoside C Sodium/potassium-transporting ATPase inhibitor